

DOTT.SSA ANNA TESSARI
CURRICULUM VITAE

INFORMAZIONI PERSONALI

Cognome e Nome	Tessari Anna
Qualifica	Medico Chirurgo, Specialista in Oncologia
Amministrazione	ULSS5 Polesana
Incarico attuale	Dirigente Medico a tempo indeterminato
Telefono Ufficio	
Email Istituzionale	Anna.tessari@aulss5.veneto.it

TITOLI DI STUDIO E PROFESSIONALI

Titolo di studio	LAUREA IN MEDICINA E CHIRURGIA con la votazione di 110/110 lode, conseguita presso l'Università degli Studi di Ferrara (2008)
Altri titoli di studio e professionali	SPECIALIZZAZIONE IN ONCOLOGIA con la votazione di 110/110 lode, conseguita presso l'Università degli Studi di Milano (2014)

ESPERIENZE PROFESSIONALI

Incarichi ricoperti	<ul style="list-style-type: none">• Da luglio 2024 ad oggi, Dirigente Medico in Oncologia a tempo indeterminato presso AULSS5 Polesana.• 2023-2024 Research Scientist (Ricercatore), Department of Cancer Biology and Genetics (Dipartimento di Biologia e Genetica Tumorale, laboratorio diretto dal Prof. Vincenzo Coppola), The Ohio State University and Comprehensive Cancer Center, Columbus, Ohio, USA• 2016-2023 Research Scientist (Ricercatore), Department of Cancer Biology and Genetics (Dipartimento di Biologia e Genetica Tumorale, laboratorio diretto dal Prof. Carlo M Croce), The Ohio State University and Comprehensive Cancer Center, Columbus, Ohio, USA• 2014-2016 Post Doctoral Fellow (Ricercatore Post-Dottorato), Department of Cancer Biology and Genetics (Dipartimento di Biologia e Genetica Tumorale, laboratorio diretto dal Prof. Carlo M Croce), The Ohio State University and Comprehensive Cancer Center, Columbus, Ohio, USA• 2009-2014 Scuola di Specializzazione in Oncologia Medica con formazione clinica presso Istituto Nazionale dei Tumori di Milano
---------------------	--

	<ul style="list-style-type: none"> 12/2008 e 12/2009 Medico Volontario, Medicina Interna e Ginecologia/Ostetricia presso St Orsola Catholic Mission Hospital, Matiri, Kenya
--	--

CAPACITÀ LINGUISTICHE

Lingua	Inglese. Capacità di lettura, scrittura ed espressione orale eccellente.
--------	--

CAPACITÀ NELL'USO DELLE TECNOLOGIE

Conoscenze informatiche	Microsoft Office. Padronanza nella gestione della cartella informatizzata con sistema Patidock attualmente in uso presso l'azienda ULSS5. Padronanza di GraphPad per analisi statistica e rappresentazione grafica. Software grafica: BioRender. Padronanza di software di analisi immagini Imaris. Software di analisi citofluorimetriche Flowjo10.
-------------------------	--

ALTRO

<p>Pubblicazioni, partecipazioni, Incarichi, ecc.</p>	<p>FORMAZIONE DI RICERCA CLINICA:</p> <ul style="list-style-type: none"> • 2014 Partecipazione a Molecular and Translational Oncology Workshop (Corso intensivo di Oncologia Molecolare e Traslazionale), Cancer Education Consortium, Chicago, Illinois, USA • 2012 Partecipazione a 14th ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research (Corso intensivo sui Metodi nella Ricerca Oncologica Clinica), Flims, Switzerland • 2010 Partecipazione a corso su GCP e Trial Clinici, Istituto Nazionale dei Tumori, Milano <p>PUBBLICAZIONI:</p> <ul style="list-style-type: none"> • Tessari A, Mills J, Anastas V, Sunilkumar D, Samadi Rad N, Lamba S, Cosentini I, Reers A, Zhu Z, Miles WO, Coppola V, Cocucci E, Magliery TJ, Shive H, Davies AE, Rizzotto L, Croce CM, Palmieri D. Acute degradation of nucleolin reveals its novel functions in cell cycle progression and cell division in triple negative breast cancer. <i>J Exp Clin Cancer Res.</i> 2025 Jul 14;44(1):204. doi: 10.1186/s13046-025-03401-y.PMID: 40653460 • Kajimura Y, Dong S, Tessari A, Orlacchio A, Thoms A, Cufaro MC, Di Marco F, Amari F, Chen M, Soliman SHA, Rizzotto L, Zhang L, Sunilkumar D, Amann JM, Carbone DP, Ahmed A, Fiermonte G, Freitas MA, Lodi A, Del Boccio P, Tessarollo L, Palmieri D, Coppola V. An in vivo "turning model" reveals new RanBP9 interactions in lung macrophages. <i>Cell Death Discov.</i> 2025 Apr 13;11(1):171. doi: 10.1038/s41420-025-02456-2.PMID: 40223093 • Capece M, Tessari A, Mills J, Rampioni Vinciguerra GL, Liu C, McElwain BK, Miles WO, Coppola V, Palmieri D, Croce CM. A novel auxin-inducible
	<p>degron system for rapid, cell cycle-specific targeted proteolysis. <i>Cell Death and Differentiation.</i> 2023 Aug 3. doi: 10.1038/s41418-023-01191-4. Online ahead of print. PMID: 37537305.</p> <ul style="list-style-type: none"> • Massa G, Tessari A, Damian S, Duca M, Tamborini E, Perrone F, Paolini B, Martinetti A, Sottotetti E, de Braud F, Cresta S, Pircher C. Uterine Tumor Resembling Sex-Cord Tumors of the Ovary (Utrosct): A Case of Long-Term Response to Pazopanib. <i>Ann Case Report.</i> 2022 Dec 19. 7: 1090. DOI: 10.29011/2574-7754.101090. • Gargiuli C, Sepe P, Tessari A, Sheetz T, Colecchia M, de Braud FGM, Procopio G, Sensi M, Verzoni E, Dugo M. Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma. <i>Cancers (Basel).</i> 2021 Jun 10;13(12):2903. doi: 10.3390/cancers13122903.

- Sheetz T, Mills J, **Tessari A**, Pawlikowski M, Braddom AE, Posid T, Zynger DL, James C, Embrione V, Parbhoo K, Foray C, Coppola V, Croce CM, Palmieri D. NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs. *Cancers (Basel)*. 2020 Jul 10;12(7):1861. doi: 10.3390/cancers12071861.
- Soliman SHA, Stark AE, Gardner ML, Harshman SW, Breece CC, Amari F, Orlacchio A, Chen M, **Tessari A**, Martin JA, Visone R, Freitas MA, La Perle KMD, Palmieri D, Coppola V. Tagging enhances histochemical and biochemical detection of Ran Binding Protein 9 in vivo and reveals its interaction with Nucleolin. *Sci Rep*. 2020 Apr 28;10(1):7138. doi: 10.1038/s41598-020-64047-8.
- **Tessari A**, Soliman SHA, Orlacchio A, Capece M, Amann JM, Visone R, Carbone DP, Palmieri D, Coppola V. RANBP9 as potential therapeutic target in non-small cell lung cancer. *J Cancer Metastasis Treat*. 2020;6:18. doi: 10.20517/2394-4722.2020.32. Epub 2020 Jun 24.
- Mills J, Capece M, Cocucci E, **Tessari A**, Palmieri D. Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure. *Int J Mol Sci*. 2019 Dec 4;20(24):6109. doi: 10.3390/ijms20246109.
- Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, **Tessari A**, de Braud F, Garassino MC, Colombo MP, Lo Russo G. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung Cancer*. 2019 Jun;132:72-78. doi: 10.1016/j.lungcan.2019.04.008. Epub 2019 Apr 8.
- Lo Russo G, **Tessari A**, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. *Front Oncol*. 2018 Dec

21;8:650. doi: 10.3389/fonc.2018.00650. eCollection 2018

- Orlacchio A, Stark AE, Foray C, Amari F, Sheetz T, Reese E, Tessari A, La Perle K, Palmieri D, Tschlis PN, Coppola V. Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethality. *PLoS One*. 2018 Sep 12;13(9):e0201030. doi: 10.1371/journal.pone.0201030. eCollection 2018
- **Tessari A**, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu ML, Mariani L, de Braud FG, Cresta S. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy? *Breast*. 2018 Aug 29;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.

- **Tessari A**, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggin M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. *Oncogene*. 2018 Aug 3. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3.
- Palmieri D, **Tessari A**, Coppola V. Scorpins in the DNA Damage Response. *Int J Mol Sci*. 2018 Jun 17;19(6). pii: E1794. doi: 10.3390/ijms19061794.
- Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, **Tessari A**, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. *ESMO Open*. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. *eCollection* 2018.
- Cona MS, Duca M, Damian S, Cresta S, de Braud F and **Tessari A**. A Case Report of Uncommon Efficacy and Favorable Safety Profile of Gemcitabine Rechallenge in Metastatic Breast Cancer. Accepted at *Austin Oncol Case Rep* 2(1): id1005 (2017)
- Galli G, **Tessari A**, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, de Braud F, Di Cosimo S. Complete remission in metastatic breast cancer: expecting the unexpected-results of a crosssectional study. *Breast Cancer*. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6. Epub 2017 Jan 5.
- Galli G, **Tessari A**, Di Cosimo S. Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of crosssectional study design and biologic considerations about disease history.

Breast Cancer. 2017 Mar 6. doi: 10.1007/s12282-017-0766-z.

- D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, **Tessari A**, De Braud F, Di Leva G, Tripodo C, Iorio MV. miR-9 and miR-200 Regulate PDGFR β Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. *Cancer Res*. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.
- Fiedler W, DeDosso S, Cresta S, Weidmann J, **Tessari A**, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. *Eur J Cancer*. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003.
- Palmieri D, Scarpa M, **Tessari A**, Uka R, Amari F, Lee C, Richmond T, Foray C, Sheetz T, Braddom A, Burd CE, Parvin JD, Ludwig T, Croce CM, Coppola V. Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. *Oncotarget*. 2016 Apr 5;7(14):18371-83. doi: 10.18632/oncotarget.7813.
- Serpico D, Porcu L, **Tessari A**, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. *Clin Transl Oncol*. 2015 Jul;17(7):530-8. doi: 10.1007/s12094-015-1274-2. Epub 2015 Jan 21.
- Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, **Tessari A**, Cathomas R, Gianni L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. *Br J Cancer*. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.
- Pusceddu S, **Tessari A**, Testa I, Procopio G. Everolimus in advanced solid tumors: when to start, early or late? *Tumori*. 2014 Jan-Feb;100(1):e2-3. doi: 10.1700/1430.15827.
- **Tessari A**, Palmieri D, Di Cosimo S. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. *Pharmgenomics Pers Med*. 2013 Dec 16;7:1-19.
- Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, **Tessari A**, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. *Med Oncol*. 2013 Sep;30(3):610. doi: 10.1007/s12032-013-0610-z. Epub 2013 May 23.

POSTER E ABSTRACT:

- **115th Annual Meeting of the American Association for Cancer**

Research; 2024 April 5-10; San Diego, California. Nastaran Samadi Rad; Joseph Mills; **Anna Tessari**; Damu Sunil Kumar; Vollter Anastas; Saranya Lamba; Ashley B Reers; Ilaria Cosentini; Zirui Zhu; Thomas J Magliery; Emanuele Cocucci; Lara Rizzotto; Dario Palmieri. *Characterization of nucleolar biological functions via Auxin inducible degron-mediated acute depletion in triple negative breast cancer cells.*

•

110th Annual Meeting of the American Association for Cancer Research; 2019 March-April 29-3; Atlanta, Georgia. Shimaa Soliman, Arturo Orlacchio, **Anna Tessari**, Marina Capece, Rosa Visone, Carlo CM Croce, Dario Palmieri, and Vincenzo Coppola. *RANBP9 presence affects levels of Tip60-mediated activation of p53 in lung cancer cells in response to DNA damage.*

•

11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine; 2019 Apr 8-12; Maui, Hawaii. **Anna Tessari**, Giuseppe Lo Russo, Marina Capece, Shimaa Soliman, Filippo De Braud, Marina C. Garassino, Harvey Pass, Carlo M. Croce and Dario Palmieri. *Novel therapeutic agents for miRNA down-regulation and Malignant Pleural Mesothelioma treatment.*

•

109th Annual Meeting of the American Association for Cancer Research; 2018 Apr 14-18; Chicago, IL. **Anna Tessari**, Meghan Pawlikowski, Kareesma Parbhoo, Olivia Willetts, Marianna Hernandez, Giovanni Nigita, Ashley Braddom, Joseph J. Mills, Dario Palmieri, Carlo M. Croce. *miR-135b mediates gemcitabine sensitivity in breast cancer cells by modulating epithelial-to-mesenchymal transition and mTOR-signaling.*

•

109th Annual Meeting of the American Association for Cancer Research; 2018 Apr 14-18; Chicago, IL. **Anna Tessari**, Kareesma Parbhoo, Meghan Pawlikowski, Matteo Fassan, Eliana Rulli, Claudia Foray, Alessandra Fabbri, Valerio Embrione, Monica Ganzinelli, Marina Capece, Massimo Broggin, Gabriella Farina, Mirko Marabese, Marina C. Garassino, Carlo Croce, Dario Palmieri, Vincenzo Coppola. *Multiple DNA-damage response pathways are modulated by RANBP9 protein in NSCLC.*

- **The International Association for the Study of Lung Cancer (IASLC) XVIII World Conference on Lung Cancer;** 2017 October 15-19, Yokohama, Japan. **A. Tessari**, D. Palmieri, M. Pawlikowski, K. Parbhoo, C. Foray, M. Fassan, K. La Perle, E. Rulli, A. Fabbri, M. Ganzinelli, V. Embrione, M. Broggin, J. Amann, D. Carbone, M. Garassino, C. Croce, V. Coppola. *RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors.* Journal of Thoracic Oncology, November 2017 Volume 12, Issue 11, Supplement 2,

Pages S2123–S2124.

- **American Urological Association Annual Meeting;** 2017 May 12-16 Boston, MA. Tyler Sheetz, Dario Palmieri, Vincenzo Coppola, **Anna Tessari**, Joseph Mills, Ashley Braddom, Erika Reese, Claudia Foray, Kareesma Parbhoo, Carlo M. Croce. *A novel therapy for castration-resistant prostate cancer through inhibition of oncogenic micrornas.* The Journal of Urology, April 2017 Volume 197, Issue 4, Supplement, Pages e1111–e1112.
- **AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics;** 2015 Nov 5-9; Boston, MA. **Tessari A**, Palmieri D, Nigita G, Veneziano D, Cresta S, Paolini B, Cona M.S, Vargo T, Reese E, Sheetz T, Coppola V, De Braud F and Croce C. *Role of miR-135b in gemcitabine sensitivity for metastatic breast cancer patients.* Mol Cancer Ther December 2015 14; C17. doi: 10.1158/1535-7163.TARG-15-C17.
- **AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics;** 2015 Nov 5-9; Boston, MA. Ashley Braddom, Timothy Richmond, Tyler Sheetz, Erika Reese, **Anna Tessari**, Christin E. Burd, Claudia De Lorenzo, Edward W. Martin Jr., Vincenzo Coppola, Michael F. Tweedle, Tatiana Oberyszyn, Carlo Maria Croce and Dario Palmieri. *Human anti-Nucleolin recombinant immunoagents as new potential tools for melanoma treatment.* Mol Cancer Ther December 2015 14; C171 doi: 10.1158/1535-7163.TARG-15-C171.
- **106th Annual Meeting of the American Association for Cancer Research** 2015 Apr 18-22; Philadelphia, PA. D. Palmieri, M. Scarpa, **A. Tessari**, R. Uka F. Amari, C. Lee, T. Richmond, T. Sheetz, J. Parvin, T. Ludwig, C. M. Croce Vincenzo Coppola. *Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.* Cancer Res August 1, 2015 75; LB-164 doi: 10.1158/1538-7445.AM2015-LB-164.

- **Annual Meeting of the American Society of Clinical Oncology;** 2014 May 30 – June 03; Chicago IL. **Anna Tessari**, Biagio Paolini, Luigi Mariani, Lorenzo Pilla, Maria Luisa Carcangiu, Angela Moliterni, Filippo G. De Braud, Sara Cresta. Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 1110).
- **104th Annual Meeting of the American Association for Cancer Research;** 2013 Apr 6-10; Washington, DC. **Anna Tessari**, Lorenzo Pilla, Biagio Paolini, Maria Luisa Carcangiu, Luigi Mariani, Angela Moliterni, Filippo De Braud, Sara Cresta. *Expression of NY-ESO-1, MAGE-A3, PRAME*

and WT1 in different subgroups of breast cancer. Abstract number LB-320.

- **55th Annual Meeting of the Italian Cancer Society.** Ilaria Plantamura, Elvira D'Ippolito, **Anna Tessari**, Sara Cresta, Rosaria Orlandi, Filippo De Braud, Elda Tagliabue, and Marilena V. Iorio. *PDGFRbeta induced miR-9 is up-regulated in triple negative breast cancer and mediates Vasculogenic Mimicry.* Abstract number V10.
- **Annual Meeting of the European Society for Medical Oncology;** 2012 September 28 - October 2; Vienna, Austria. Puma E, Mariani P, Damian S, Dazzani MC, De Benedictis E, Parati MC, Sica L, **Tessari A**, De Braud F, Moliterni A. *Neoadjuvant Chemotherapy in Operable Breast Cancer: data from the ASTER study (AT for 3 cycles followed by CMF for 3 cycles).* *Annals of Oncology* 23 (Supplement 9): ix95–ix115, 2012, 269p.
- **San Antonio Breast Cancer Symposium 2012.** Zambetti M, Guidetti A, Carlo-Stella C, De Benedictis E, **Tessari A**, Balzarini A, Caraceni A, Gianni L, Gianni AM. *Sorafenib for treatment of Breast Cancer relate Lymphedema,* Abstract Book, P2-12-08.
- **Annual Meeting of the American Society of Clinical Oncology;** 2013 May 31 – June 04; Chicago IL. Silvia Damian, **Anna Tessari**, Giuseppe Capri, Paola Mariani, Giulia Valeria Bianchi, Gabriella Mariani, Francesca Ricchini, Lorenzo Sica, Elena De Benedictis, Sara Cresta, Rodolfo Lanocita, Carlo Spreafico. *Hepatic trans-arterial chemoembolization (TACE) in metastatic breast cancer.* *J Clin Oncol* 31, 2013 (suppl; abstr e12017).

- **Annual Meeting of the American Society of Clinical Oncology;** 2013 May 31 – June 04; Chicago IL. Walter Fiedler, Cristiana Sessa, Luca Gianni, Sara Cresta, Henning Schulze-Bergkamen, Jens Weidmann, Sara De Dosso, **Anna Tessari**, Marc Oliver Salzberg, Hans Baumeister, Antje Danielczyk, Bruno Dietrich, Johannes Nippgen, Steffen Goletz *First-in- human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.* J Clin Oncol 31, 2013 (suppl; abstr 3008).
- **Annual Meeting of the American Society of Clinical Oncology;** 2013 May 31 – June 04; Chicago IL. Filippo Pietrantonio, **Anna Tessari**, Rosalba Miceli, Pamela Biondani, Federica Perrone, Adele Testi, Elena Tamborini, Giuseppe Pelosi, Luigi Mariani, Giuseppe Fanetti, Arpine Gevorgyan, Ilaria Bossi, Maria Di Bartolomeo, Filippo G. De Braud. *Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.* J Clin Oncol 31, 2013 (suppl; abstr 3641).
- **Annual Meeting of the American Society of Clinical Oncology;** 2013 May

	<p>31 – June 04; Chicago IL. Giuseppe Fanetti, Pamela Biondani, Anna Tessari, Flavia Melotti, Massimo Milione, Filippo G. DeBraud, Federica Perrone, Rosalba Miceli, Luigi Mariani, Arpine Gevorgyan, Maria Di Bartolomeo, Filippo Pietrantonio. <i>Pathologic response, KRAS status, and bevacizumab: The Bermuda triangle for outcome prediction after hepatic colorectal cancer metastases (HCRM) resection</i>. J Clin Oncol 31, 2013 (suppl; abstr e14716).</p> <ul style="list-style-type: none"> • XIV Congresso Nazionale Associazione Italiana di Oncologia Medica; 2012 October 27-29, Roma, Italy. Pamela Biondani, Filippo Pietrantonio, Federica Perrone, Massimo Milione, Filippo de Braud, Gaia Bertarelli, Luigi Mariani, Flavia Melotti, Giuseppe Pelosi, Diego Cortinovis, Manuela Scuro, Anna Tessari and Maria Di Bartolomeo. <i>ERCC1, BAX and TP53 for prognostic assessment in Advanced Colorectal Cancer (CRC) Pts randomized to First-line UFT/LEUCOVORIN (LV) plus IRINOTECAN (TEGAFIRI) versus UFT/LV plus OXALIPLATIN (TEGAFOX)</i>. I supplementi di TUMORI, a Journal of Experimental and Clinical Oncology, Volume 13, Number 3, October 2012, B49. • XIV Congresso Nazionale Associazione Italiana di Oncologia Medica; 2012 October 27-29, Roma, Italy. Filippo Pietrantonio, Pamela Biondani, Filippo Venturini, Felicia Giacobbe, Federica Perrone, Federica Villa, Vincenzo Ricci, Maria Di Bartolomeo, Andrea Cassingena, Lisa Pietrogiovanna, Vito Amoroso, Maria Cristina Petrella, Anna Tessari, Daniela Nonnis and Filippo de Braud. <i>BRAF versus KRAS G12V Mutation for outcome prediction in Metastatic Colorectal Cancer (mCRC): a multicenter, matched-pair, casecontrol study</i>. I supplementi di TUMORI, a Journal of Experimental and Clinical Oncology, Volume 13, Number 3, October 2012, B30. <p>RICONOSCIMENTI:</p> <ul style="list-style-type: none"> • 2014-2016 Pelotonia Post-Doctoral Fellowship (Borsa di Studio “Pelotonia” per ricercatori post-dottorato in ambito oncologico presso The Ohio State University and Comprehensive Cancer Center, Columbus, Ohio, USA) • 2008 Premio Carlo Urbani dell’Ordine dei Medici e Chirurghi di Ferrara per Giovani Medici <p>USMLE (United States Medical Licence Examination):</p> <ul style="list-style-type: none"> • STEP1: Sostenuto e superato (04/11/2022) • STEP 2: Sostenuto e superato (14/07/2023) • OET (Occupational English Test): Sostenuto e superato (18/08/2023)
--	---